human cd200fc  (R&D Systems)

Journal: OncoImmunology

Article Title: CD200 and CD200R1 are differentially expressed and have differential prognostic roles in non-small cell lung cancer

doi: 10.1080/2162402x.2020.1746554

Figure Lengend Snippet: Figure 4. Evaluation of CD200R1 functions with CD200R1 knockdown and CD200Fc administration. (a) Western blots in the left part showing the representing protein levels after CD200R1 knockdown with siRNA in PC9 and H358 cells, respectively. Bar graphs on the right part show western blotting quantification of pAKT/AKT and pERK/ERK in the siRNA1 and siRNA2 groups relative to those in negative controls (NCs). The data represent the mean ± SD, N = 4. *P <.05 and **P <.001 vs. NC (one-way ANOVA). (b–c) Effect of CD200R1 knockdown with siRNA on cell proliferation in PC9 and H358 cells as analyzed by CCK-8 assays. The negative control (NC) was scramble RNA-transfected cells. The data represent the mean ± SD, N = 5. *P <.05 and **P <.001 vs. NC (one-way ANOVA). (d) Effect of CD200Fc treatment on cell proliferation in PC9 cells as analyzed by CCK-8 assays. (e) Effect of CD200Fc treatment on endogenous mRNA expression levels of immune markers in PC9 cells as analyzed by RT-qPCR. Gene expression was normalized to the expression of GAPDH and is shown relative to vehicle control expression. The data represent the mean ± SD, N = 3. *P <.05 and **P <.001 vs. vehicle (Student’s t-test).

Article Snippet: To investigate the binding of CD200 to CD200R1, we used recombinant human CD200Fc protein (cat no. 2724-CD; R&D Systems, Minneapolis, MN, USA).

Techniques: Knockdown, Western Blot, CCK-8 Assay, Negative Control, Transfection, Expressing, Quantitative RT-PCR, Gene Expression, Control

Journal: OncoImmunology

Article Title: CD200 and CD200R1 are differentially expressed and have differential prognostic roles in non-small cell lung cancer

doi: 10.1080/2162402x.2020.1746554

Figure Lengend Snippet: Figure 5. Enriched gene profiles in tumors with high CD200R1 expression and differentially-expressed genes in response to CD200Fc administration as assessed by cDNA microarray. (a) Volcano plots showing the significantly overexpressed genes among tumors with high CD200R1 expression using online RNA sequencing data (NSCLC, TCGA, Provisional) including 230 adenocarcinomas (ADCs), and 501 squamous cell carcinomas (SCCs). The overexpressed genes in high CD200R1-expressing tumors are surrounded by dashed lines in the volcano plots, and these were additionally analyzed based on GSEA Investigation gene set analysis using the hallmark gene set. (b) Log2 fold expression changes of the 35 most strongly up- and downregulated genes in PC9 cells treated with CD200Fc versus expression in cells treated with vehicle (N = 2). (c) GSEA analysis comparing up- and downregulated cancer hallmark gene sets and oncogenic signature gene sets in PC9 cells treated with CD200Fc versus expression in cells treated with vehicle. (d–e) Expression of certain genes differentially-expressed upon CD200Fc administration in PC9 cells based on validation by RT-qPCR. Gene expression was normalized to the expression of GAPDH and is shown relative to the vehicle-treated control expression. The data represent the mean ± SD, N = 3. *P <.05 and **P <.001 vs. vehicle (Student’s t-test).

Article Snippet: To investigate the binding of CD200 to CD200R1, we used recombinant human CD200Fc protein (cat no. 2724-CD; R&D Systems, Minneapolis, MN, USA).

Techniques: Expressing, Microarray, RNA Sequencing, Biomarker Discovery, Quantitative RT-PCR, Gene Expression, Control